Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HQY Stock Forecast 2026-2027
$85.60
Current Price
$7.40B
Market Cap
Buy 14
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to HQY Price Targets
+51.9%
To High Target of $130.00
+44.3%
To Median Target of $123.50
+4.0%
To Low Target of $89.00
HQY Price Momentum
-13.1%
1 Week Change
-10.6%
1 Month Change
-15.0%
1 Year Change
-6.6%
Year-to-Date Change
-26.6%
From 52W High of $116.65
+15.6%
From 52W Low of $74.07
📊 TOP ANALYST CALLS
Did HQY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if HealthEquity is one of their latest high-conviction picks.
Latest HQY Stock Price Targets & Analyst Predictions
Based on our analysis of 27 Wall Street analysts, HQY has a bullish consensus with a median price target of $123.50 (ranging from $89.00 to $130.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $85.60, the median forecast implies a 44.3% upside. This outlook is supported by 14 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from David Larsen at BTIG, projecting a 51.9% upside. Conversely, the most conservative target is provided by David Roman at Goldman Sachs, suggesting a 4.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HQY Analyst Ratings
14
Buy
1
Hold
1
Sell
HQY Price Target Range
Low
$89.00
Average
$123.50
High
$130.00
Current: $85.60
Latest HQY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HQY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 9, 2026 | Goldman Sachs | David Roman | Sell | Downgrade | $89.00 |
| Jan 8, 2026 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $125.00 |
| Dec 9, 2025 | Barclays | Glen Santangelo | Overweight | Initiates | $118.00 |
| Dec 4, 2025 | JP Morgan | Alexei Gogolev | Overweight | Maintains | $129.00 |
| Dec 4, 2025 | BTIG | David Larsen | Buy | Reiterates | $130.00 |
| Dec 4, 2025 | Barrington Research | Alexander Paris | Outperform | Maintains | $125.00 |
| Dec 4, 2025 | Citizens | Constantine Davides | Market Outperform | Maintains | $122.00 |
| Nov 13, 2025 | BMO Capital | Sean Dodge | Market Perform | Initiates | $100.00 |
| Oct 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $120.00 |
| Sep 3, 2025 | JP Morgan | Anne Samuel | Overweight | Maintains | $126.00 |
| Sep 3, 2025 | Jefferies | Glen Santangelo | Buy | Maintains | $134.00 |
| Sep 3, 2025 | RBC Capital | Daniel R. Perlin | Outperform | Maintains | $110.00 |
| Sep 3, 2025 | Barrington Research | Alexander Paris | Outperform | Maintains | $125.00 |
| Aug 29, 2025 | Barrington Research | Alexander Paris | Outperform | Maintains | $125.00 |
| Aug 28, 2025 | RBC Capital | Daniel R. Perlin | Outperform | Maintains | $109.00 |
| Jul 8, 2025 | Raymond James | C. Gregory Peters | Strong Buy | Reiterates | $120.00 |
| Jun 11, 2025 | Jefferies | Buy | Maintains | $N/A | |
| Jun 5, 2025 | Deutsche Bank | George Hill | Buy | Maintains | $115.00 |
| Jun 5, 2025 | Barrington Research | Alexander Paris | Outperform | Maintains | $125.00 |
| Jun 4, 2025 | JMP Securities | Constantine Davides | Market Outperform | Maintains | $117.00 |
HealthEquity Inc. (HQY) Competitors
The following stocks are similar to HealthEquity based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
HQY
HealthEquity
mkt cap
8.14B
HealthEquity Inc. (HQY) Financial Data
HealthEquity Inc. has a market capitalization of $7.40B with a P/E ratio of 39.3x. The company generates $1.29B in trailing twelve-month revenue with a 14.9% profit margin.
Revenue growth is +7.2% quarter-over-quarter, while maintaining an operating margin of +24.8% and return on equity of +9.0%.
Valuation Metrics
Market Cap
$7.40B
Enterprise Value
$8.03B
P/E Ratio
39.3x
PEG Ratio
0.1x
Price/Sales
5.7x
Growth & Margins
Revenue Growth (YoY)
+7.2%
Gross Margin
+70.8%
Operating Margin
+24.8%
Net Margin
+14.9%
EPS Growth
+806.4%
Financial Health
Cash/Price Ratio
+4.2%
Current Ratio
4.1x
Debt/Equity
48.2x
ROE
+9.0%
ROA
+5.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
HealthEquity Inc. (HQY) Business Model
About HealthEquity Inc.
What They Do
Administers health savings accounts and consumer benefits.
Business Model
The company generates revenue by managing health savings accounts (HSAs) and offering related financial services. By providing a technology-driven platform, it enables individuals and families to save for medical expenses efficiently, while also facilitating tax-advantaged savings. Additionally, HealthEquity partners with healthcare providers and insurers to enhance the financial decision-making process for consumers.
Additional Information
Headquartered in Draper, Utah, HealthEquity serves millions of consumers and plays a crucial role in the healthcare financial sector. Its services not only support personal savings but also contribute to improving the overall efficiency of healthcare funding and management.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
3,105
CEO
Mr. Scott R. Cutler J.D.
Country
United States
IPO Year
2014
Website
www.healthequity.comHealthEquity Inc. (HQY) Latest News & Analysis
Latest News
Quick Summary
Zacks Style Scores can assist investors in selecting strong, market-beating stocks for their portfolios.
Why It Matters
The Zacks Style Scores highlight stocks with potential for outperformance, guiding investors to make informed portfolio decisions based on quantitative analysis.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
HQY reports strong growth in Health Savings Accounts (HSA) and efficiency gains from AI, alongside solid Q3 results; however, data security threats pose a significant risk.
Why It Matters
Strong HSA growth and AI efficiencies signal potential for increased profitability, while data security risks could impact future performance and investor confidence.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
HealthEquity (HQY) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing optimism about its earnings prospects, which may lead to a potential rise in stock value.
Why It Matters
HealthEquity's upgrade to a Zacks Rank #2 signals increased earnings potential, likely boosting investor confidence and stock demand.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
HealthEquity (HQY) shows strong growth potential that may lead to significant market outperformance.
Why It Matters
HealthEquity's strong growth potential suggests higher returns, making it an attractive investment compared to broader market performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
HealthEquity, Inc. (HQY) held its Q3 2026 earnings call, providing insights into financial performance and future outlook. Further details can be found in the full transcript.
Why It Matters
HealthEquity's Q3 2026 earnings call provides insights into financial performance, growth prospects, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
In Q3, revenue rose 7% to $322.2 million. Net income per diluted share increased to $0.59 from $0.06, while non-GAAP net income per diluted share grew 29% to $1.01.
Why It Matters
Strong revenue growth and significant increases in net income indicate robust financial health, potentially boosting investor confidence and affecting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About HQY Stock
What is HealthEquity Inc.'s (HQY) stock forecast for 2026?
Based on our analysis of 27 Wall Street analysts, HealthEquity Inc. (HQY) has a median price target of $123.50. The highest price target is $130.00 and the lowest is $89.00.
Is HQY stock a good investment in 2026?
According to current analyst ratings, HQY has 14 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $85.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HQY stock?
Wall Street analysts predict HQY stock could reach $123.50 in the next 12 months. This represents a 44.3% increase from the current price of $85.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is HealthEquity Inc.'s business model?
The company generates revenue by managing health savings accounts (HSAs) and offering related financial services. By providing a technology-driven platform, it enables individuals and families to save for medical expenses efficiently, while also facilitating tax-advantaged savings. Additionally, HealthEquity partners with healthcare providers and insurers to enhance the financial decision-making process for consumers.
What is the highest forecasted price for HQY HealthEquity Inc.?
The highest price target for HQY is $130.00 from David Larsen at BTIG, which represents a 51.9% increase from the current price of $85.60.
What is the lowest forecasted price for HQY HealthEquity Inc.?
The lowest price target for HQY is $89.00 from David Roman at Goldman Sachs, which represents a 4.0% increase from the current price of $85.60.
What is the overall HQY consensus from analysts for HealthEquity Inc.?
The overall analyst consensus for HQY is bullish. Out of 27 Wall Street analysts, 14 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $123.50.
How accurate are HQY stock price projections?
Stock price projections, including those for HealthEquity Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 11:15 AM UTC